The DOI matches its Crossref record; 32 of the 32 references it cites were found in a registry or an index.
Antitumor Activity of Nivolumab in Recurrent and Metastatic Nasopharyngeal Carcinoma: An International, Multicenter Study of the Mayo Clinic Phase 2 Consortium (NCI-9742)
Open accessAbstract
Purpose: This multinational study evaluated the antitumor activity of nivolumab in nasopharyngeal carcinoma (NPC). Tumor and plasma-based biomarkers were investigated in an exploratory analysis. Patients and Methods: Patients with multiply pretreated recurrent or metastatic NPC were treated with nivolumab until disease progression. The primary end point was objective response rate (ORR) and secondary end points included survival and toxicity. The expression of programmed death-ligand 1 (PD-L1) and human leukocyte antigens A and B in archived tumors and plasma clearance of Epstein-Barr virus DNA were correlated with ORR and survival. Results: A total of 44 patients were evaluated and the overall ORR was 20.5% (complete response, n = 1; partial response, n = 8). Nine patients received nivolumab for > 12 months (20%). The 1-year overall survival rate was 59% (95% CI, 44.3% to 78.5%) and 1-year progression-free survival (PFS) rate was 19.3% (95% CI, 10.1% to 37.2%). There was no statistical correlation between ORR and the biomarkers; however, a descriptive analysis showed that the proportion of patients who responded was higher among those with PD-L1 positive tumors (> 1% expression) than those with PD-L1-negative tumors. The loss of expression of one or both human leukocyte antigen class 1 proteins was associated with better PFS than when both proteins were expressed (1-year PFS, 30.9% v 5.6%; log-rank P = .01). There was no association between survival and PD-L1 expression or plasma Epstein-Barr virus DNA clearance. There was no unexpected toxicity to nivolumab. Conclusion: Nivolumab has promising activity in NPC and the 1-year overall survival rate compares favorably with historic data in similar populations. Additional evaluation in a randomized setting is warranted. The biomarker results were hypothesis generating and validation in larger cohorts is needed.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
PD-1 and PD-L1 Immune Checkpoint Blockade to Treat Breast Cancer
Hartkopf, A. D., Taran, F.-A., Wallwiener, M., Walter, C. B., Krämer, B., Grischke, E.-M., & Brucker, S. Y. (2016) · Breast Care · doi:10.1159/000453569 · Cited by 30,845
Safety, activity, and immune correlates of anti–PD-1 antibody in cancer
Topalian, S. L., Hodi, F. S., Brahmer, J. R., Gettinger, S. N., Smith, D. C., McDermott, D. F., Powderly, J. D., Carvajal, R. D., Sosman, J. A., Atkins, M. B., et al. (2012) · New England Journal of Medicine · doi:10.1056/nejmoa1200690 · Cited by 12,628
Nivolumab for Recurrent Squamous-Cell Carcinoma of the Head and Neck
Ferris, R. L., Blumenschein, G., Fayette, J., Guigay, J., Colevas, A. D., Licitra, L., Harrington, K., Kasper, S., Vokes, E. E., Even, C., et al. (2016) · New England Journal of Medicine · doi:10.1056/nejmoa1602252 · Cited by 5,101
Genomic and Transcriptomic Features of Response to Anti-PD-1 Therapy in Metastatic Melanoma
Hugo, W., Zaretsky, J. M., Sun, L., Song, C., Moreno, B. H., Hu-Lieskovan, S., Berent-Maoz, B., Pang, J., Chmielowski, B., Cherry, G., et al. (2016) · Cell · doi:10.1016/j.cell.2016.02.065 · Cited by 3,448
Mutations Associated with Acquired Resistance to PD-1 Blockade in Melanoma
Zaretsky, J. M., Garcia-Diaz, A., Shin, D. S., Escuin-Ordinas, H., Hugo, W., Hu-Lieskovan, S., Torrejon, D. Y., Abril-Rodriguez, G., Sandoval, S., Barthly, L., et al. (2016) · New England Journal of Medicine · doi:10.1056/nejmoa1604958 · Cited by 3,237
Champiat, S., Dercle, L., Ammari, S., Massard, C., Hollebecque, A., Postel-Vinay, S., Chaput, N., Eggermont, A., Marabelle, A., Soria, J.-C., et al. (2017) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-16-1741 · Cited by 1,190
Muro, K., Chung, H. C., Shankaran, V., Geva, R., Catenacci, D., Gupta, S., Eder, J. P., Golan, T., Le, D. T., Burtness, B., et al. (2016) · The Lancet Oncology · doi:10.1016/s1470-2045(16)00175-3 · Cited by 1,121
Chow, L. Q. M., Haddad, R., Gupta, S., Mahipal, A., Mehra, R., Tahara, M., Berger, R., Eder, J. P., Burtness, B., Lee, S.-H., et al. (2016) · Journal of Clinical Oncology · doi:10.1200/jco.2016.68.1478 · Cited by 857
Chen, B. J., Chapuy, B., Ouyang, J., Sun, H. H., Roemer, M. G. M., Xu, M. L., Yu, H., Fletcher, C. D. M., Freeman, G. J., Shipp, M. A., et al. (2013) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-13-0855 · Cited by 843
Immune escape to PD-L1/PD-1 blockade: seven steps to success (or failure)
Kim, J. M., & Chen, D. S. (2016) · Annals of Oncology · doi:10.1093/annonc/mdw217 · Cited by 648
Development of immuno-oncology drugs — from CTLA4 to PD1 to the next generations
Hoos, A. (2016) · Nature Reviews Drug Discovery · doi:10.1038/nrd.2015.35 · Cited by 601
Johnson, D. B., Estrada, M. V., Salgado, R., Sanchez, V., Doxie, D. B., Opalenik, S. R., Vilgelm, A. E., Feld, E., Johnson, A. S., Greenplate, A. R., et al. (2016) · Nature Communications · doi:10.1038/ncomms10582 · Cited by 566
Pesce, S., Greppi, M., Tabellini, G., Rampinelli, F., Parolini, S., Olive, D., Moretta, L., Moretta, A., & Marcenaro, E. (2017) · Journal of Allergy and Clinical Immunology · doi:10.1016/j.jaci.2016.04.025 · Cited by 465
Hsu, C., Lee, S.-H., Ejadi, S., Even, C., Cohen, R. B., Le Tourneau, C., Mehnert, J. M., Algazi, A., van Brummelen, E. M. J., Saraf, S., et al. (2017) · Journal of Clinical Oncology · doi:10.1200/jco.2017.73.3675 · Cited by 464
Fang, W., Zhang, J., Hong, S., Zhan, J., Chen, N., Qin, T., Tang, Y., Zhang, Y., Kang, S., Zhou, T., et al. (2014) · Oncotarget · doi:10.18632/oncotarget.2608 · Cited by 398
The genomic landscape of nasopharyngeal carcinoma
Lin, D.-C., Meng, X., Hazawa, M., Nagata, Y., Varela, A. M., Xu, L., Sato, Y., Liu, L.-Z., Ding, L.-W., Sharma, A., et al. (2014) · Nature Genetics · doi:10.1038/ng.3006 · Cited by 366
Self-citationPD-1 mediates functional exhaustion of activated NK cells in patients with Kaposi sarcoma
Beldi-Ferchiou, A., Lambert, M., Dogniaux, S., Vély, F., Vivier, E., Olive, D., Dupuy, S., Levasseur, F., Zucman, D., Lebbé, C., et al. (2016) · Oncotarget · doi:10.18632/oncotarget.12150 · Cited by 312
Exome and genome sequencing of nasopharynx cancer identifies NF-κB pathway activating mutations
Li, Y. Y., Chung, G. T. Y., Lui, V. W. Y., To, K.-F., Ma, B. B. Y., Chow, C., Woo, J. K., Yip, K. Y., Seo, J., Hui, E. P., et al. (2017) · Nature Communications · doi:10.1038/ncomms14121 · Cited by 309
Self-citationChan, A. T. C., Hsu, M.-M., Goh, B. C., Hui, E. P., Liu, T.-W., Millward, M. J., Hong, R.-L., Whang-Peng, J., Ma, B. B. Y., To, K. F., et al. (2005) · Journal of Clinical Oncology · doi:10.1200/jco.2005.02.147 · Cited by 287
Self-citationKinetics of plasma Epstein-Barr virus DNA during radiation therapy for nasopharyngeal carcinoma.
Lo, Y. M. D., Leung, S. F., Chan, L. Y. S., Chan, A. T. �., Lo, K. W., Johnson, P. J., & Huang, D. P. (2000) · PubMed · Cited by 236
Self-citationPD-L1 biomarker testing for non-small cell lung cancer: truth or fiction?
Grigg, C., & Rizvi, N. A. (2016) · Journal for ImmunoTherapy of Cancer · doi:10.1186/s40425-016-0153-x · Cited by 206
Roemer, M. G. M., Advani, R. H., Redd, R. A., Pinkus, G. S., Natkunam, Y., Ligon, A. H., Connelly, C. F., Pak, C. J., Carey, C. D., Daadi, S. E., et al. (2016) · Cancer Immunology Research · doi:10.1158/2326-6066.cir-16-0201 · Cited by 189
Costimulatory molecule B7‐H1 in primary and metastatic clear cell renal cell carcinoma
Thompson, R. H., Gillett, M. D., Cheville, J. C., Lohse, C. M., Dong, H., Webster, W. S., Chen, L., Zincke, H., Blute, M. L., Leibovich, B. C., et al. (2005) · Cancer · doi:10.1002/cncr.21470 · Cited by 174
Rejection versus escape: the tumor MHC dilemma
Garrido, F., Ruiz-Cabello, F., & Aptsiauri, N. (2017) · Cancer Immunology, Immunotherapy · doi:10.1007/s00262-016-1947-x · Cited by 158
Kluger, H. M., Zito, C. R., Turcu, G., Baine, M. K., Zhang, H., Adeniran, A., Sznol, M., Rimm, D. L., Kluger, Y., Chen, L., et al. (2017) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-16-3146 · Cited by 158
Inoue, H., Park, J., Kiyotani, K., Zewde, M. G., Miyashita, A., Jinnin, M., Kiniwa, Y., Okuyama, R., Tanaka, R., Fujisawa, Y., et al. (2016) · OncoImmunology · doi:10.1080/2162402x.2016.1204507 · Cited by 137
López‐Nevot, M. Á., Esteban, F., FERRON, A. D., Gutiérrez, J., Mr, O., Romero, C., Huelin, C., Ruiz‐Cabello, F., & Garrido, F. (1989) · British Journal of Cancer · doi:10.1038/bjc.1989.45 · Cited by 127
A Phase II Study of Pazopanib in Asian Patients with Recurrent/Metastatic Nasopharyngeal Carcinoma
Lim, W., Ng, Q., Ivy, P. S., Leong, S. S., Singh, O., Chowbay, B., Gao, F., Thng, C. H., Goh, B.-C., Tan, D. S.-W., et al. (2011) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-10-3409 · Cited by 122
Self-citationPD-1/PD-L1 Blockade Therapy for Tumors with Downregulated MHC Class I Expression
Šmahel, M. (2017) · International Journal of Molecular Sciences · doi:10.3390/ijms18061331 · Cited by 90
Zhu, Q., Cai, M.-Y., Chen, C.-L., Hu, H., Lin, H., Li, M., Weng, D., Zhao, J.-J., Guo, L., & Xia, J. (2017) · OncoImmunology · doi:10.1080/2162402x.2017.1312240 · Cited by 85
Hui, E. P., Ma, B. B. Y., Loong, H. H.-F., Mo, F. K. F., Li, L., King, A. D., Wang, K., Ahuja, A. T., Chan, C. M. L., Hui, C. W. C., et al. (2018) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-17-1667 · Cited by 69
Self-citationCharacterization of PD-L1 expression and immune cell infiltration in nasopharyngeal cancer
Chan, O. S. H., Kowanetz, M., Ng, W. T., Koeppen, H., Chan, L. K., Yeung, R. M. W., Wu, H., Amler, L. C., & Mancao, C. (2017) · Oral Oncology · doi:10.1016/j.oraloncology.2017.02.002 · Cited by 57
Cited by
Chen, Y.-P., Chan, A. T. C., Le, Q.-T., Blanchard, P., Sun, Y., & Ma, J. (2019) · The Lancet · doi:10.1016/s0140-6736(19)30956-0 · Cited by 3,077
Self-citationWang, Y., Zhou, S., Yang, F., Qi, X., Wang, X., Guan, X., Shen, C., Duma, N., Vera Aguilera, J., Chintakuntlawar, A., et al. (2019) · JAMA Oncology · doi:10.1001/jamaoncol.2019.0393 · Cited by 862
Cohen, E. E. W., Bell, R. B., Bifulco, C. B., Burtness, B., Gillison, M. L., Harrington, K. J., Le, Q.-T., Lee, N. Y., Leidner, R., Lewis, R. L., et al. (2019) · Journal for ImmunoTherapy of Cancer · doi:10.1186/s40425-019-0662-5 · Cited by 722
Nasopharyngeal carcinoma: an evolving paradigm
Wong, K. C. W., Hui, E. P., Lo, K.-W., Lam, W. K. J., Johnson, D., Li, L., Tao, Q., Chan, K. C. A., To, K.-F., King, A. D., et al. (2021) · Nature Reviews Clinical Oncology · doi:10.1038/s41571-021-00524-x · Cited by 546
Self-citationFang, W., Yang, Y., Ma, Y., Hong, S., Lin, L., He, X., Xiong, J., Li, P., Zhao, H., Huang, Y., et al. (2018) · The Lancet Oncology · doi:10.1016/s1470-2045(18)30495-9 · Cited by 489
Metadata
- Authors
- Ma, B. B. Y., Lim, W.-T., Goh, B.-C., Hui, E. P., Lo, K.-W., Pettinger, A., Foster, N. R., Riess, J. W., Agulnik, M., Chang, A. Y. C., Chopra, A., Kish, J. A., Chung, C. H., Adkins, D. R., Cullen, K. J., Gitlitz, B. J., Lim, D. W., To, K.-F., Chan, K. C. A., Lo, Y. M. D., King, A. D., Erlichman, C., Yin, J., Costello, B. A., & Chan, A. T. C.
- Venue
- Journal of Clinical Oncology
- Published
- 2018-05-10
- Volume
- 36
- Issue
- 14
- Pages
- 1412-1418
- ISSN
- 0732-183X (ISSN-L)
- 1527-7755
- OpenAlex
- W2794739281
- Cited by
- 451
- References
- 32
- FWCI
- 15.42
- Type
- journal article
- Language
- en
- Open access
- green
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.